scholarly journals TNF-α, TNF-β, IL-6, and IL-10 Polymorphisms in Patients with Lung Cancer

2005 ◽  
Vol 21 (3) ◽  
pp. 157-165 ◽  
Author(s):  
Carola Seifart ◽  
Alexandra Plagens ◽  
Astrid Dempfle ◽  
Ursula Clostermann ◽  
Claus Vogelmeier ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Inflammatory Responses ◽  
Cancer Susceptibility ◽  
Population Control ◽  
Matched Pair ◽  
German Population ◽  
Matched Pair Analysis ◽  
Genotype Frequencies ◽  
Tnf Α ◽  
Study Population

Apart from cigarette smoking, genetic factors seem to be of importance in the development of lung cancer. The present case-control study investigated frequencies of five inflammatory response gene polymorphisms (TNF-α-308, TNF-β-Intron1-252, IL-6-174, IL-10-819 and IL-10-1082) in patients with lung cancer and controls. The study population consisted of 117 patients with lung cancer (77 patients with NSCLC, including 40 Squamous Cell Carcinoma and 26 Adenocarcinoma, and 40 patients with SCLC), 117 matched controls without pulmonary disease and 243 healthy individuals (population control). Genotype analyses revealed no difference in genotype frequencies using matched-pair analysis. However, in comparison to the population control, the IL-10-1082 genotypes carrying the G allele appeared with higher frequency in the SCLC group (p= 0.006) [SCLC: 84.6%, population controls: 64.6%]. This yields an odds ratio of 3.01 for SCLC (95% CI = [1.21, 7.48]). No associations were seen for all other polymorphisms analysed. The study raises the possibility of a correlation between the IL-10-1082_G allele and the presence of SCLC in a German population. The functional IL-10-1082 polymorphism correlates with altered IL-10 levels and might influence lung cancer susceptibility by altered inflammatory responses in the airways.

scholarly journals No evidence to support the impact of migration background on treatment response rates and cancer survival: a retrospective matched-pair analysis in Germany

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Roman Rüdiger ◽  
Franziska Geiser ◽  
Manuel Ritter ◽  
Peter Brossart ◽  
Mignon-Denise Keyver-Paik ◽  
...  
Keyword(s):  
Treatment Response ◽  
Cancer Survival ◽  
Survival Rates ◽  
Migration Background ◽  
Comprehensive Cancer Center ◽  
Matched Pair ◽  
Cancer Center ◽  
German Population ◽  
Matched Pair Analysis ◽  
Immigrant Background

Abstract Background Immigration has taken the central stage in world politics, especially in the developed countries like Germany, where the continuous flow of immigrants has been well documented since 1960s. Strikingly, emerging data suggest that migrant patients have a poorer response to the treatment and lower survival rates in their new host country, raising concerns about health disparities. Herein, we present our investigation on the treatment response rate and cancer survival in German patients with and without an immigrant background that were treated at our comprehensive cancer center in Germany. Methods Initially, we considered 8162 cancer patients treated at the Center for Integrated Oncology (CIO), University Hospital Bonn, Germany (April 2002–December 2015) for matched-pair analysis. Subsequently, the German patients with a migration background and those from the native German population were manually identified and catalogued using a highly specific name-based algorithm. The clinical parameters such as demographic characteristics, tumor characteristics, defined staging criteria, and primary therapy were further adjusted. Using these stringent criteria, a total of 422 patients (n = 211, Germans with migration background; n = 211, native German population) were screened to compare for the treatment response and survival rates (i.e., 5-year overall survival, progression-free survival, and time to progression). Results Compared to the cohort with migration background, the cohort without migration background was slightly older (54.9 vs. 57.9 years) while having the same sex distribution (54.5% vs. 55.0% female) and longer follow-up time (36.9 vs. 42.6 months). We did not find significant differences in cancer survival (5-year overall survival, P = 0.771) and the response rates (Overall Remission Rate; McNemar’s test, P = 0.346) between both collectives. Conclusion Contrary to prior reports, we found no significant differences in cancer survival between German patients with immigrant background and native German patients. Nevertheless, the advanced treatment protocols implemented at our comprehensive cancer center may possibly account for the low variance in outcome. To conduct similar studies with a broader perspective, we propose that certain risk factors (country-of-origin-specific infections, dietary habits, epigenetics for chronic diseases etc.) should be considered, specially in the future studies that will recruit new arrivals from the 2015 German refugee crisis.

scholarly journals 2490

2017 ◽  
Vol 1 (S1) ◽  
pp. 30-30
Author(s):  
Mary S. Rodriguez-Rabassa ◽  
Kaumudi Joshipura Jinraj ◽  
Maribel Campos Rivera ◽  
Vasiliki Michopoulos ◽  
Yasuhiro Yamamura
Keyword(s):  
Executive Functions ◽  
Emotional Processing ◽  
Inflammatory Responses ◽  
Descriptive Analysis ◽  
Cross Sectional Study ◽  
Affect Recognition ◽  
Healthy Weight ◽  
Cross Sectional ◽  
Tnf Α ◽  
Study Population

OBJECTIVES/SPECIFIC AIMS: Childhood obesity has become an issue of some concern worldwide. Some reviews and a recent study in adults have indicated that obesity-related inflammatory responses produce brain damage. However, studies exploring associations between inflammation and executive functions in children are overlooked. Therefore, the objective of this cross-sectional study is to determine whether difficulties in executive functions and emotional processing are associated with obesity and inflammation. METHODS/STUDY POPULATION: We have recruited 12 of a total of 60 children aged 6–8 years old. They have completed the NIH Toolbox Cognition Battery and the NEPSY II Affect Recognition tests. Samples of plasma and saliva were collected to quantify inflammatory biomarkers cytokines (IL-6 and TNF-α) assay by Luminex procedure. We performed descriptive analysis and Mann-Whitney U test to compare obese Versus nonobese groups. RESULTS/ANTICIPATED RESULTS: Obese children have lower scores in measures of affect recognition than healthy weight children. They also showed higher median scores in both salivary and plasma IL-6 and TNF-α. DISCUSSION/SIGNIFICANCE OF IMPACT: Although no statistical differences were found among groups in either measurement, these preliminary data based on the initial recruitment suggest that children with higher body mass index may have difficulties in emotional processing. More data will be available after completing recruitment to determine if the association between obesity and affect recognition is significant and if it is mediated by inflammation.

Comparative Analysis of the 3-Year Persistence Rate with Second-Line Vedolizumab and Tumor Necrosis Factor-α Inhibitors in Patients with Inflammatory Bowel Disease Followed in Gastroenterology Practices in Germany

2020 ◽  
Vol 38 (6) ◽  
pp. 466-473
Author(s):  
Ulf Helwig ◽  
Fiona Braegger ◽  
Karel Kostev ◽  
Carsten Schmidt
Keyword(s):  
Tumor Necrosis ◽  
Matched Pair ◽  
Second Line ◽  
Matched Pair Analysis ◽  
Therapy Initiation ◽  
Tnf Α ◽  
Inflammatory Bowel ◽  
Factor Α ◽  
Pair Analysis ◽  
Necrosis Factor

<b><i>Background:</i></b> Our goal was to investigate the 3-year persistence rates with second-line vedolizumab and tumor necrosis factor-α (TNF-α) inhibitors (i.e., adalimumab, golimumab, infliximab) in patients with inflammatory bowel disease (IBD) who were followed in gastroenterology practices in Germany. <b><i>Methods:</i></b> This study included patients aged ≥18 years who had received prescriptions for second-line biological drugs in Germany between 2014 and 2017 (<i>n</i> = 5,150) retrieved from the longitudinal prescription database. Vedolizumab users were matched to adalimumab, golimumab, and infliximab users based on age, sex, and index year. The primary outcome of the study was the rate of persistence with vedolizumab compared with the rate of persistence with adalimumab, golimumab, and infliximab within 3 years of second-line therapy initiation in IBD patients. Persistence was estimated as therapy time without discontinuation, with discontinuation being defined as at least 90 days without any prescription for the biological drug of interest. <b><i>Results:</i></b> After matching patients who had received vedolizumab with those who had received adalimumab, the rate of persistence after 3 therapy years was 30.3% for vedolizumab and 27.9% for adalimumab (log-rank <i>p</i> = 0.005). The corresponding figures were 27.8 and 20.8% in the vedolizumab-golimumab matched-pair analysis (log-rank <i>p</i> &#x3c; 0.001) and 29.5 and 25.2% in the vedolizumab-infliximab matched-pair analysis (log-rank <i>p</i> value = 0.008). Vedolizumab was associated with a significant 0.85-, 0.72-, and 0.86-fold decrease in the risk of discontinuation within 3 years of therapy initiation compared to adalimumab, golimumab, and infliximab, respectively. <b><i>Conclusions:</i></b> Treatment persistence was higher for vedolizumab than for TNF-α inhibitors up to 3 years after initiating second-line biological therapy.

Matched-pair comparison of outcome of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 7040-7040
Author(s):  
Julia Shelkey ◽  
Achilles Fakiris ◽  
Malcolm M. DeCamp ◽  
Laura Nyshel Medford-Davis ◽  
John Charles Flickinger ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Overall Survival ◽  
Prognostic Factors ◽  
Small Cell Lung Cancer ◽  
Clinical Stage ◽  
Small Cell ◽  
Matched Pair ◽  
Small Cell Lung ◽  
Matched Pair Analysis ◽  
Pair Analysis

7040 Background: Stereotactic body radiotherapy (SBRT) is an alternative to surgery alone for certain patients with clinical stage I non-small cell lung cancer (NSCLC), but comparing their effectiveness is difficult because of differences in patient selection and staging. Methods: Two databases were combined which contained 132 patients treated by lobectomy (LR) and 48 by sublobar resection (SLR) and 137 patients managed with SBRT after negative staging between 1999-2009. We compared rates of overall survival (OS), disease-free survival (DFS), and locoregional control (LRC) between patients treated with surgery and SBRT to each other and in relation to possible prognostic factors. We then performed a matched-pair analysis comparing surgery and SBRT results. Median follow-up for the entire study population was 25.8 months. Results: On univariate analysis, OS was significantly correlated with histology, the Charlson Comorbidity Index, tumor size, aspirin use, and use of SBRT; DFS was correlated only with histology; and no variable was significantly correlated with LRC. Multivariate analysis found improved OS in patients with adenocarcinoma and those undergoing surgical resection. The NSCLC “not otherwise specified” histology was associated with poorer DFS. Overall survival was significantly poorer for SBRT patients in the matched-pair analysis than for patients treated with surgery, but DFS and LRC were not significantly different between these groups. Conclusions: Our retrospective study has demonstrated similar LRC and DFS in patients treated with SBRT or surgery, but worse OS in the former group, when patients were matched for prognostic factors. Our investigation suggests that randomized trials are needed to eliminate selection bias in treatment assignment in order to accurately compare outcomes between these approaches.

Matched-Pair Analysis of High Dose Versus Standard Dose Definitive Chemoradiation for Locally Advanced Non–Small-Cell Lung Cancer

2017 ◽  
Vol 18 (2) ◽  
pp. 149-155 ◽  
Author(s):  
Matthew D. Johnson ◽  
Karna Sura ◽  
Victor S. Mangona ◽  
Alexander Glick ◽  
Michelle Wallace ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Standard Dose ◽  
Locally Advanced ◽  
Small Cell ◽  
Matched Pair ◽  
High Dose ◽  
Small Cell Lung ◽  
Matched Pair Analysis ◽  
Pair Analysis

Differences in mutation patterns of diagnostic versus post-chemotherapy samples in patients with metastatic non-small cell lung cancer (NSCLC).

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 8079-8079
Author(s):  
William Nassib William ◽  
Heidi S. Erickson ◽  
Caimiao Wei ◽  
Nana Hanson ◽  
Ximing Tang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Matched Pair ◽  
Wild Type ◽  
Dna Recovery ◽  
Molecular Abnormalities ◽  
Metastatic Nsclc ◽  
Paired Samples ◽  
Matched Pair Analysis ◽  
Formalin Fixed Paraffin Embedded ◽  
Pre Treatment

8079 Background: Many clinical trials in metastatic NSCLC patients who failed first-line chemotherapy have utilized pre-treatment, diagnostic tissues for marker assessment. BATTLE was a randomized, biopsy-driven clinical study in patients with metastatic NSCLC previously treated with systemic therapy. Fresh biopsies were obtained at the time of enrollment for biomarker evaluation. We hypothesized that molecular abnormalities found at the time of enrolment in BATTLE would differ from baseline, pre-chemotherapy, diagnostic tissue. Methods: We isolated DNA (SPRI-TE-based DNA recovery and cleanup methodology) from 82 matched pre-chemotherapy and BATTLE formalin-fixed paraffin-embedded specimens. Mutations were assessed by MALDI-TOF MS (MassArray, Sequenom Inc) using a lung cancer panel of 16 genes/140 assays (AKT1, BRAF, CTNNB1, EGFR, ERBB2, FGFR3, HRAS, KRAS, MEK1, MEK2, MET, NRAS, PIK3CA, PIK3R1, PTEN, and STK11) and were compared between pre-chemotherapy versus BATTLE samples. Results: Mutations were identified in 25 pre-chemotherapy samples (14 K-RAS, 5 EGFR, 3 PIK3CA, 1 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). Conversely, 29 BATTLE samples had at least one mutation (14 K-RAS, 7 EGFR, 5 PIK3CA, 2 STK11, 1 PTEN, 1 HRAS, 1 CTNNB1). For the matched pair analysis, 46 patients had wild-type tumors both in pre-chemotherapy and BATTLE samples. 11 patients had wild-type tumors in pre-chemotherapy samples, but had a mutation identified in BATTLE samples (4 K-RAS, 4 EGFR, 2 PIK3CA, 1 STK11). 7 patients had a mutation in pre-chemotherapy samples, but no mutations in BATTLE samples (4 K-RAS, 2 EGFR, 1 HRAS). The remaining 18 patients had mutations in both the pre-chemotherapy and BATTLE samples; of these, 2 had different mutations in the paired samples (both within the same genes, 1 KRAS, 1 PIK3CA). Overall, there was a 24% gene mutation discordance rate between pre-chemotherapy and BATTLE samples. Conclusions: Profiling of fresh biopsies may more accurately reflect molecular abnormalities present in the tumor at the time of initiation of salvage therapy, underscoring the importance of real time tissue collection in biomarker-driven studies in this setting (V Foundation, DoD).

Sign in / Sign up

Export Citation Format

Share Document